ClinicalTrials.gg
CompletedNCT07135986Updated Oct 19, 2026

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China

A Phase 3 interventional study of MenACYW conjugate vaccine and MenACYW135 polysaccharide vaccine in Meningococcal Infection and Healthy Volunteers, sponsored by Sanofi. Completed at 4 sites in China. Open to participants aged 2 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Updated Oct 19, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,602
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Meningococcal Infections by Sanofi — 2 open to participants now, 2 under way, 1 of them phase 3. Meningococcal Infections · Sanofi.

Enrollment
7th of 51
1,602 · median 378
Started
2025
the only one that year
Phase 3
25 of 57
1 open now
Registered
56th of 57
by date

Among the 57 studies in Meningococcal Infections by Sanofi, this one is the 7th largest by enrollment of the 51 interventional ones that give a count, is the only one that started in 2025, is one of 25 in phase 3, and was the 56th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

2 of the 57 studies in Meningococcal Infections by Sanofi are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Meningococcal Infections by Sanofi, or all of them as a file.
02

Study summary

This is a Phase 3, modified double-blind, randomized, parallel-group, active-controlled, multicenter study with 2 arms and 4 groups to evaluate the immunogenicity and safety of MenACYW conjugate vaccine in children and adolescents versus control meningococcal vaccines licensed in China.

Study details include:

  • The study duration will be approximately 180 days.
  • The vaccination visit will be Visit 1.
  • The visit frequency will be 2 on-site visits with a 30-day interval. A safety visit/telephone call is planned on the ninth day after the vaccination for all groups; a safety follow-up telephone call is planned for all groups 180 days post the last vaccination.
Read the detailed description

The duration of each participant's participation will be approximately 180 days.

03

Conditions studied

  • Meningococcal Infection
  • Healthy Volunteers
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • For Cohort I: Aged 7 to 17 years on the day of inclusion ("7 to 17 years" means from the day of the 7th birthday to the day before the 18th birthday.). For Cohort II: Aged 2 to 6 years on the day of inclusion (2 to 6 years" means from the day of the 2nd birthday to the day before the 7th birthday.)
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding

Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy; or long-term systemic therapy
  • History of meningococcal infection
  • History of any neurologic disorders
  • History of Guillain-Barré syndrome
  • History of an Arthus-type reaction after a previous dose of tetanus toxoid-containing vaccine
  • At high risk for meningococcal infection during the trial
  • Known systemic hypersensitivity to any of the vaccine components
  • Self-reported thrombocytopenia, contraindicating intramuscular vaccination.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.
  • Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
  • Moderate or severe acute illness/infection
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion.
  • Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine in the 4 weeks following trial vaccination.
  • The time since last vaccination of meningococcal vaccine was 2 years or less.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,602 participants (actual)

Study arms

  • Experimental
    Group 1 MenACYW1-dose schedule

    1 dose of MenACYW conjugate vaccine to participants aged 7 through 17 years of age

    Biological: MenACYW conjugate vaccine

  • Active comparator
    Group 2 MenACYW135 Ps 1-dose schedule

    1 dose of MenACYW135 polysaccharide vaccine to participants aged 7 through 17 years of age

    Biological: MenACYW135 polysaccharide vaccine

  • Experimental
    Group 3 MenACYW1-dose schedule

    1 dose of MenACYW conjugate vaccine to participants aged 2 through 6 years of age

    Biological: MenACYW conjugate vaccine

  • Active comparator
    Group 4 Royal MenAC1-dose schedule

    1 dose of Royal's MenAC conjugate vaccine to participants aged 2 through 6 years of age

    Biological: MenAC conjugate vaccine

Interventions

  • BiologicalMenACYW conjugate vaccine

    Pharmaceutical form:Liquid solution-Route of administration:Intramuscular (IM) injection

    Also known as: MenQuadfi

  • BiologicalMenACYW135 polysaccharide vaccine

    Pharmaceutical form: Lyophilized powder-Route of administration:IM injection

  • BiologicalMenAC conjugate vaccine

    Pharmaceutical form:Lyophilized powder-Route of administration:IM injection

06

What researchers measure

Primary outcomes

  1. Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W

    30 days postvaccination rSBA titer ≥1:8 for participants with prevaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days postvaccination for participants with pre vaccination rSBA titer ≥1:8

    Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)

  2. Participants 7 through 17 years of age (Cohort I): Geometric mean titers (GMTs) of antibodies against meningococcal serogroups A, C, Y, and W

    Antibodies titers are expressed as geometric mean titers

    Time frame: Day 31 (post- vaccination)

  3. Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups W and Y will be assessed in participants receiving MenACYW conjugate vaccine

    30 days postvaccination rSBA titer ≥1:8 for participants with prevaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-vaccination for participants with pre vaccination rSBA titer ≥1:8

    Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)

  4. Participants 2 through 6 years of age (Cohort II): Vaccine seroresponse to meningococcal serogroups A and C

    30 days postvaccination rSBA titer ≥1:8 for participants with prevaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days postvaccination for participants with pre vaccination rSBA titer ≥1:8

    Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)

  5. Participants 2 through 6 years of age (Cohort II): Geometric mean titers (GMTs) of antibodies against meningococcal serogroups A and C

    Antibody titers are expressed as geometric mean titers

    Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)

  6. Participants 2 through 6 years of age (Cohort II): Vaccine seroresponse to meningococcal serogroups W and Y in participants receiving MenACYW conjugate vaccine

    30 days post-vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30◦days post-vaccination for participants with pre vaccination rSBA titer ≥1:8

    Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)

Secondary outcomes

  1. Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W (Group 1)

    30 days post vaccination rSBA titer ≥1:8 for participants with pre vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post vaccination for participants with pre vaccination rSBA titer ≥1:8

    Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)

  2. Number of participants with immediate adverse events (AEs)

    Unsolicited systemic AEs that occur within 30 minutes after vaccination

    Time frame: Within 30 minutes post-vaccination

  3. Presence of solicited injection site reactions

    Solicited injection site reactions include injection site pain, erythema and swelling

    Time frame: Within 7 days post-vaccination

  4. Presence of solicited systemic reactions

    Solicited systemic reactions include fever, headache, malaise and myalgia

    Time frame: Within 7 days post-vaccination

  5. Presence of unsolicited AEs

    Time frame: Within 30 days post-vaccination

  6. Presence of SAEs

    SAEs, including adverse events of special interest (AESIs), reported throughout the study

    Time frame: Up to Day 181 post-vaccination

  7. Participants 7 through 17 years of age (Cohort I): Antibody titers against meningococcal serogroups A, C, Y, and W in Groups 1 and 2

    Antibody titers measured by rSBA titer ≥1:8, ≥1:128

    Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)

  8. Participants 2 through 6 years of age (Cohort II): Antibody titers against meningococcal serogroups A, C, Y, and W in Group 3 and against meningococcal serogroups A and C in Group 4

    Antibody titers measured by rSBA titer ≥1:8, ≥1:128

    Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)

  9. Participants 2 through 6 years of age (Cohort II): Antibody titers in terms of GMTs against meningococcal serogroups Y and W in Group 3

    Antibodies titers are expressed as geometric mean titers

    Time frame: Day 01 (pre-vaccination) and Day 31 (post- vaccination)

07

Study locations

4 sites
  • Investigational Site Number : 1561000
    Nanning, Guangxi 530028, China
  • Investigational Site Number : 1561001
    Jingxi, 533899, China
  • Investigational Site Number : 1561003
    Liuzhou, 545100, China
  • Investigational Site Number : 1561002
    Tengzhou, 543399, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in May 2026, 7 months.

Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 7 months is below that.

Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 22, 2025
StartActual
Sep 26, 2025
Primary completionActual
May 1, 2026
CompletionActual
Sep 24, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 19, 2026
Study completion
Sep 23, 2026→Sep 24, 2026 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Completed
    Study completion Sep 23, 2026→Sep 24, 2026 (now actual)
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07135986
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Sep 26, 2025
Primary completion
May 1, 2026
Completion
Sep 24, 2026
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion